Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for…
If you just looked at formal Buy and Sell ratings from Wall Street analysts, you might assume that everything is still fine and hopeful for Gilead Sciences.
Jon C. Ogg Gilead Sciences Inc. (NASDAQ: GILD) released third-quarter earnings report after markets closed on Tuesday. Despite negative news coming out on Tuesday with former presidential candidate Bernie Sanders taking a shot at the…
Chris Lange Although Gilead has been falling for about a year now, the valuation is looking more favorable — assuming Gilead is not a value trap. The earnings report will help shed some light…
Chris Lange 24/7 Wall St. has put together a preview of Pfizer, Starbucks and some of the major companies reporting their quarterly results this week.
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Americans generally would like to spend less money on health care. One way that this can be and will be accomplished is through the continued use and expanded use of generic drugs.
These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.
October 13, 2016: Here are four stocks trading with relatively heavy volume among 80 equities making new 52-week lows in Thursday’s session. On the NYSE, decliners led advancers by 2 to 1…
October 12, 2016: Here are four stocks trading with relatively heavy volume among 52 equities making new 52-week lows in Wednesday’s session. On the NYSE, advancers led decliners by a slim margin…
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
October 11, 2016: Here are four stocks trading with relatively heavy volume among 69 equities making new 52-week lows in Tuesday’s session. On the NYSE, decliners led advancers by about 7 to 1…
October 7, 2016: Here are four stocks trading with relatively heavy volume among 49 equities making new 52-week lows in Friday’s session. On the NYSE, decliners led advancers by more than 2…
October 6, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in Thursday’s session. On the NYSE, decliners led advancers by a slight margin…
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
